Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Jan 27;100(2):246-50.
doi: 10.1038/sj.bjc.6604838. Epub 2009 Jan 6.

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

J P Neoptolemos  1 , D D Stocken, C Tudur Smith, C Bassi, P Ghaneh, E Owen, M Moore, R Padbury, R Doi, D Smith, M W Büchler
Affiliations
Meta-Analysis

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

J P Neoptolemos et al. Br J Cancer. .

Abstract

The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI=0.55-0.88) P=0.003, and the median survival of 23.2 (95% CI=20.1-26.5) months with 5FU/FA vs 16.8 (95% CI=14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ESPAC-1 trial design.
Figure 2
Figure 2
Kaplan–Meier survival curves stratified by trial.
Figure 3
Figure 3
Meta-analysis of ESPAC-1, ESPAC-1 plus ESPAC-3 (v1) trials for overall survival.
Figure 4
Figure 4
Kaplan–Meier overall survival curves non-stratified by trial.
Figure 5
Figure 5
Kaplan–Meier overall survival curves stratified by trial and treatment group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL (2007) Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117(5): 1305–1313 - PMC - PubMed
    1. Bucher H, Guyatt G, Griffith L, Walter S (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 50(6): 683–691 - PubMed
    1. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19(9): 1592–1599 - PubMed
    1. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR, Benson AB (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol ASCO annual meeting proceedings (post-meeting edition). vol 26, no. 15S (20 May Supplement): 4506)
    1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW, European Study Group for Pancreatic Cancer (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358(9293): 1576–1585 - PubMed

Publication types

MeSH terms